In a new lawsuit, a pharmacy benefit manager (PBM) alleges that a pharmaceutical company raised the price of its opioid overdose reversal medicine, naloxone, essentially price-gouging consumers. However, the lawsuit also shows that the PBM kept an increasing amount in rebates for itself, which the PBM reclassified as “administrative fees,” as the price of the drug increased. The PBM also dropped the treatment from its preferred list of medications, making the PBM at least partially responsible for reducing access to the treatment. Read more here.
Last Updated on May 13, 2020 by Aimed Alliance
